RT Journal Article
SR Electronic
T1 Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.17.23292359
DO 10.1101/2023.07.17.23292359
A1 Fava, Andrea
A1 Buyon, Jill
A1 Magder, Laurence
A1 Hodgin, Jeff
A1 Rosenberg, Avi
A1 Demeke, Dawit S.
A1 Rao, Deepak A.
A1 Arazi, Arnon
A1 Celia, Alessandra Ida
A1 Putterman, Chaim
A1 Anolik, Jennifer H.
A1 Barnas, Jennifer
A1 Dall’Era, Maria
A1 Wofsy, David
A1 Furie, Richard
A1 Kamen, Diane
A1 Kalunian, Kenneth
A1 James, Judith A.
A1 Guthridge, Joel
A1 Atta, Mohamed G.
A1 Trujillo, Jose Monroy
A1 Fine, Derek
A1 Clancy, Robert
A1 Belmont, H. Michael
A1 Izmirly, Peter
A1 Apruzzese, William
A1 Goldman, Daniel
A1 Berthier, Celine C.
A1 Hoover, Paul
A1 Hacohen, Nir
A1 Raychaudhuri, Soumya
A1 Davidson, Anne
A1 Diamond, Betty
A1 Accelerating Medicines Partnership in RA/SLE network
A1 Petri, Michelle
YR 2023
UL http://medrxiv.org/content/early/2023/07/18/2023.07.17.23292359.abstract
AB Lupus nephritis (LN) is a pathologically heterogenous autoimmune disease linked to end-stage kidney disease and mortality. Better therapeutic strategies are needed as only 30-40% of patients completely respond to treatment. Noninvasive biomarkers of intrarenal inflammation may guide more precise approaches. Because urine collects the byproducts of kidney inflammation, we studied the urine proteomic profiles of 225 LN patients (573 samples) in the longitudinal Accelerating Medicines Partnership (AMP) in RA/SLE cohort. Urinary biomarkers of monocyte/neutrophil degranulation (i.e., PRTN3, S100A8, azurocidin, catalase, cathepsins, MMP8), macrophage activation (i.e., CD163, CD206, galectin-1), wound healing/matrix degradation (i.e., nidogen-1, decorin), and IL-16 characterized the aggressive proliferative LN classes and significantly correlated with histological activity. A decline of these biomarkers after 3 months of treatment predicted the 1-year response more robustly than proteinuria, the standard of care (AUC: CD206 0.92, EGFR 0.9, CD163 0.89, proteinuria 0.8, p<0.01). Candidate biomarkers were validated and provide new potentially treatable targets. We propose these biomarkers of intrarenal immunological activity as noninvasive tools to diagnose LN, guide treatment, and as surrogate endpoints for clinical trials. These findings provide new insights into the processes involved in LN activity. This dataset (matching other AMP omics) is a public resource to generate and test hypotheses and validate biomarkers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the AMP Rheumatoid Arthritis and Lupus Network. AMP is a public-private partnership (AbbVie Inc., Arthritis Foundation, Bristol-Myers Squibb Co., GlaxoSmithKline plc, Lupus Foundation of America, Lupus Research Alliance, Janssen Pharmaceutica, Merck Sharp & Dohme Corp., National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pfizer Inc., Rheumatology Research Foundation, Sanofi, and Takeda Pharmaceuticals International Inc.) created to develop new ways of identifying and validating promising biological targets for diagnostics and drug development. See Supplemental Acknowledgments for details on network authors. This work was supported by NIH grants UH2-AR067676, UH2-AR067677, UH2-AR067679, UH2-AR067681, UH2-AR067685, UH2- AR067688, UH2-AR067689, UH2-AR067690, UH2-AR067691, UH2-AR067694, UM2- AR067678, and AR074096. The Oklahoma Rheumatic Disease Research Cores Center is funded by NIH P30AR073750. The Hopkins Lupus Cohort is funded by NIH AR 69572. Dr Fava is supported by NIH R01DK134625, the Jerome L. Greene Foundation, the Cupid Foundation, and the Lupus Foundation of America G-2104-01274.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human study protocols were approved by the institutional review boards (IRBs) at each participating site, and written informed consent was obtained from all participants. Patients were enrolled at Johns Hopkins University, New York University, Albert Einstein College of Medicine, University of Rochester Medical Center, Northwell Health, University of California San Francisco, Medical University of South Carolina, University of California San Diego, Cedars-Sinai Medical Center, University of Michigan, Texas University El Paso, and University of California Los Angeles. For healthy controls, IRB approval was obtained from the University of Cincinnati and Oklahoma Medical Research Foundation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes